<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Approach to reperfusion therapy for acute ischemic stroke
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Approach to reperfusion therapy for acute ischemic stroke
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Approach to reperfusion therapy for acute ischemic stroke
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jamary Oliveira-Filho, MD, MS, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Owen B Samuels, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            José Biller, MD, FACP, FAAN, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan A Edlow, MD, FACEP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alejandro A Rabinstein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2894992328">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The key factor in successful reperfusion therapy of acute ischemic stroke is early treatment. Nonetheless, selection of appropriate candidates for reperfusion demands a neurologic evaluation and a neuroimaging study. In addition, reperfusion therapy for acute stroke requires a system that coordinates pre-hospital emergency services, emergency medicine, stroke neurology, intensive care services, interventional neuroradiology, and neurosurgery to provide optimal treatment.
        </p>
        <p>
         This topic will review the use of reperfusion therapy for patients with acute ischemic stroke, focusing on early thrombolytic therapy with intravenous thrombolysis (IVT). The administration of IVT for acute ischemic stroke, including dosing, monitoring, and complications, is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16134.html" rel="external">
          "Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use"
         </a>
         .)
        </p>
        <p>
         Mechanical thrombectomy is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H510877031">
         <span class="h1">
          REPERFUSION THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The immediate goal of reperfusion therapy for acute ischemic stroke is to restore blood flow to the regions of brain that are ischemic but not yet infarcted. The long-term goal is to improve outcome by reducing stroke-related disability and mortality. Options for reperfusion therapy that are proven effective include intravenous thrombolysis (IVT) and mechanical thrombectomy (MT).
        </p>
        <p class="headingAnchor" id="H749851587">
         <span class="h2">
          Intravenous thrombolysis
         </span>
        </p>
        <p class="headingAnchor" id="H2187332181">
         <span class="h3">
          Alteplase
         </span>
         <span class="headingEndMark">
          —
         </span>
         IVT with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         is the mainstay of treatment for acute ischemic stroke, provided that treatment is initiated within 4.5 hours of the time last known well  (
         <a class="graphic graphic_algorithm graphicRef141876" href="/z/d/graphic/141876.html" rel="external">
          algorithm 1
         </a>
         ). Eligibility criteria are outlined in the table  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         ). Because the benefit of alteplase is time dependent, it is critical to treat patients as quickly as possible. Alteplase, a recombinant tissue plasminogen activator (tPA), initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converting entrapped plasminogen to plasmin. In turn, plasmin breaks up the thrombus.
        </p>
        <p class="headingAnchor" id="H938416610">
         <span class="h4">
          Benefit by time to treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         IVT with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         improves functional outcome at three to six months when given within 4.5 hours of ischemic stroke onset [
         <a href="#rid1">
          1-8
         </a>
         ].
        </p>
        <p>
         The benefit of IVT for acute ischemic stroke decreases continuously over time from symptom onset, as shown in meta-analyses of randomized trials [
         <a href="#rid1">
          1,3,4,9
         </a>
         ] and a registry that analyzed data from over 58,000 patients treated with IVT within 4.5 hours of ischemic stroke symptom onset [
         <a href="#rid2">
          2
         </a>
         ]. In the registry, each 15-minute reduction in the time to initiation of IVT treatment was associated with an
         <strong>
          increase
         </strong>
         in the odds of walking independently at discharge (4 percent) and being discharged to home rather than an institution (3 percent) and a
         <strong>
          decrease
         </strong>
         in the odds of death before discharge (4 percent) and symptomatic hemorrhagic transformation of infarction (4 percent) [
         <a href="#rid2">
          2
         </a>
         ]. Similarly, another study of over 61,000 patients treated with IVT found that shorter door-to-needle times were associated with lower all-cause mortality at one year and a reduced risk of hospital readmission at one year [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         A 2014 meta-analysis evaluated individual patient data from 6756 patients (including more than 1700 who were older than age 80 years) with acute ischemic stroke who were allocated to IVT or control in the NINDS, ATLANTIS, ECASS (1, 2, and 3), EPITHET, and IST-3 trials [
         <a href="#rid4">
          4
         </a>
         ]. The primary outcome measure was the proportion of patients achieving a good stroke outcome at three or six months as defined by a modified Rankin scale score  (
         <a class="graphic graphic_table graphicRef75411" href="/z/d/graphic/75411.html" rel="external">
          table 2
         </a>
         ) of 0 or 1 (ie, no significant disability). The following observations were reported:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment within 3 hours of stroke onset,
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         led to a good outcome for 33 percent, versus 23 percent for control (odds ratio [OR] 1.75, 95% CI 1.35-2.27). The number needed to treat (NNT) for one additional patient to achieve a good outcome was 10.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment from 3 to 4.5 hours, the proportion with a good outcome in the
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         and control groups was 35 and 30 percent (OR 1.26, 95% CI 1.05-1.51, NNT 20).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment beyond 4.5 hours, the proportion with a good outcome in the
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         and control groups was no longer significant at 33 and 31 percent (OR 1.15, 95% CI 0.95-1.40, NNT 50).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         was similar regardless of patient age or stroke severity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          Alteplase
         </a>
         increased the risk of symptomatic intracranial hemorrhage (6.8 percent, versus 1.3 percent for control, OR 5.55, 95% CI 4.01-7.70); the number needed to harm (NNH) for one additional patient to have a symptomatic intracranial hemorrhage was 18. Alteplase also increased the risk of fatal intracranial hemorrhage within seven days (2.7 versus 0.4 percent, OR 7.14, 95% CI 3.98-12.79, NNH 44); this risk was similar regardless of age, stroke severity, or treatment delay. Alteplase treatment had no significant effect on other early or late causes of death.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Death at 90 days was slightly higher in the
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         group (17.9 percent, versus 16.5 percent in the control group, hazard ratio 1.11, 95% CI 0.99-1.25), a result that just missed statistical significance.
        </p>
        <p>
        </p>
        <p>
         In agreement with other meta-analyses [
         <a href="#rid1">
          1,3,7
         </a>
         ], these observations confirm that the sooner IVT is initiated, the more likely it is to be beneficial, and that the benefit extends to treatment started within 4.5 hours of stroke onset [
         <a href="#rid4">
          4
         </a>
         ]. The results also show that
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         is beneficial regardless of patient age, stroke severity, or the associated increased risk of symptomatic or fatal intracranial hemorrhage in the first days after alteplase treatment. The odds of a favorable three-month outcome decrease as the interval from stroke onset to start of alteplase treatment increases  (
         <a class="graphic graphic_figure graphicRef66764" href="/z/d/graphic/66764.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Beyond 4.5 hours, harm may exceed benefit. However, less robust data suggest possible benefit for patients presenting in the extended time window (4.5 hours to 9 hours from stroke onset), or with wake-up stroke, who are selected by advanced neuroimaging, as discussed in the section that follows.
        </p>
        <p class="headingAnchor" id="H959844664">
         <span class="h4">
          Benefit with imaging selection of patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited clinical trial evidence suggests that IVT is beneficial for select patients who wake up with stroke more than 4.5 hours after they were last known well or those who have unknown time of symptom onset,
         <strong>
          if
         </strong>
         they meet imaging criteria indicative of recent cerebral infarction and/or significant salvageable brain tissue. However, results have been inconsistent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The placebo-controlled Wake-Up Stroke trial selected 500 adults with unwitnessed stroke onset who had an ischemic parenchymal brain lesion on MRI diffusion-weighted imaging but no corresponding hyperintensity on FLAIR [
         <a href="#rid11">
          11
         </a>
         ]. This imaging mismatch (diffusion positive/FLAIR negative) correlates with a stroke onset time of 4.5 hours or less [
         <a href="#rid12">
          12
         </a>
         ]. Nearly 90 percent of enrolled patients awoke from sleep with stroke symptoms. The trial excluded patients last known to be well within 4.5 hours, since they would fulfill standard eligibility criteria for
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         ; the trial also excluded patients who were to receive MT. At 90 days, a favorable outcome (defined by a score of 0 or 1 on the modified Rankin Scale [mRS]) was more likely for patients assigned to intravenous alteplase compared with those assigned to placebo (53 versus 42 percent, adjusted OR 1.61, 95% CI 1.09-2.36). However, the mortality rate was nonsignificantly higher in the alteplase group (4 versus 1 percent, OR 3.38, 95% CI 0.92-12.52), as was the rate of symptomatic intracranial hemorrhage (2.0 versus 0.4 percent, OR 4.95, 95% CI 0.57-42.87). Limitations to the trial include stopping early (for lack of funding) and exclusion of patients planned for MT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The EXTEND trial was stopped early after publication of the Wake-Up Stroke trial. EXTEND enrolled 225 adults (of a planned 310) who had hypoperfused but salvageable brain tissue on automated perfusion imaging (with computed tomography [CT] or MRI) and could be treated between 4.5 and 9 hours after the onset of ischemic stroke or awoke with stroke symptoms, if within 9 hours from the midpoint of sleep [
         <a href="#rid13">
          13
         </a>
         ]. Patients were randomly assigned to intravenous
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         or to placebo. At 90 days, a favorable outcome (defined by a score of 0 or 1 on the mRS) was more likely for the intravenous alteplase group compared with the placebo group, after adjustment for age and clinical severity at baseline (35 versus 30 percent, risk ratio [RR] 1.44, 95% CI 1.01-2.06). However, there was no difference between treatment groups in unadjusted analysis (RR 1.2, 95% CI 0.82-1.76). Symptomatic intracranial hemorrhage within 36 hours of treatment was increased with alteplase (6 versus 1 percent) and mortality was nonsignificantly higher with alteplase (12 versus 9 percent). Limitations to the trial include stopping early and lack of efficacy in unadjusted analyses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the ECASS 4 trial, stopped early for slow recruitment, 119 patients (of a planned 264) with acute ischemic stroke and salvageable brain tissue identified by MRI were randomly assigned to treatment with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         or placebo between 4.5 and 9 hours after the onset of symptoms [
         <a href="#rid14">
          14
         </a>
         ]. At 90 days, there was no difference between the alteplase and placebo groups in the mRS distribution (OR 1.20, 95% CI 0.63-2.27); mortality was nonsignificantly higher with alteplase (12 versus 7 percent).
        </p>
        <p>
        </p>
        <p>
         A meta-analysis pooled individual patient data (n = 414) from three trials (EXTEND, ECASS 4, and EPITHET) of intravenous
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         that used imaging to identify and treat patients with salvageable brain tissue who had ischemic stroke 4.5 to 9 hours after onset or had wake-up stroke [
         <a href="#rid15">
          15
         </a>
         ]. There was a higher rate of excellent functional outcome (defined by a mRS score 0 of 1) at three months for patients assigned to alteplase compared with those assigned to placebo (36 versus 29 percent, adjusted odds ratio [OR] 1.86, 95% CI 1.15-2.99). Symptomatic intracerebral hemorrhage was more frequent in the alteplase group (5 versus 0.5 percent), but this result did not nullify the overall benefit of alteplase. Limitations to this meta-analysis include small sample size and early stopping of two of the included trials (EXTEND and ECASS 4). Another meta-analysis of four trials (including Wake-Up Stroke, EXTEND, and ECASS 4) with individual patient data from over 843 patients reported similar findings [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Although this approach seems promising, additional trials are needed to confirm the efficacy and safety of IVT using imaging selection of patients with a stroke onset time &gt;4.5 hours or an unknown stroke onset time [
         <a href="#rid17">
          17
         </a>
         ]. Advanced imaging with MRI (DWI and FLAIR), MRI perfusion, or CT perfusion appears to be essential to determine if the cerebral infarction is recent and if there is significant salvageable brain tissue. Results of the TWIST trial suggest that selecting patients with noncontrast head CT alone (to exclude hemorrhage or large infarction) is unlikely to identify patients with wake-up stroke who will benefit from IVT [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2646531377">
         <span class="h4">
          Risk of intracerebral hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with IVT within 4.5 hours of acute ischemic stroke onset is associated with an increased early risk of intracerebral hemorrhage, but this risk is offset by later benefit in the form of reduced disability (see
         <a class="local">
          'Benefit by time to treatment'
         </a>
         above) [
         <a href="#rid4">
          4
         </a>
         ]. In clinical trials of intravenous
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         , the rates of symptomatic intracerebral hemorrhage were 5 to 7 percent [
         <a href="#rid4">
          4,19
         </a>
         ], using the National Institute of Neurological Disorders and Stroke (NINDS) definition. In addition, most community-based studies of intravenous alteplase have shown similar rates [
         <a href="#rid20">
          20-24
         </a>
         ]. These studies suggest that IVT can be used safely to treat acute ischemic stroke in routine clinical practice. The number needed to harm (NNH) with IVT is very high, because most cases of symptomatic intracerebral hemorrhage occur in patients with severe deficits and poor anticipated prognosis before lysis [
         <a href="#rid25">
          25
         </a>
         ]. Also, some hemorrhages occur in areas of the brain that are already infarcted and so do not result in additional measurable deficits. As an example from the NINDS trials, for an outcome of severely disabled or dead (defined by an mRS score ≥4) with IVT-related symptomatic hemorrhage, the NNH was 126, and for a worsened outcome (defined by an mRS score ≥1), the NNH ranged from approximately 30 to 40.
        </p>
        <p>
         Differences in the criteria used to define symptomatic intracerebral hemorrhage likely account for much of the variability in the rates of hemorrhage reported in different trials [
         <a href="#rid26">
          26
         </a>
         ]. The NINDS trial definition of symptomatic intracerebral hemorrhage includes any hemorrhagic transformation temporally related to any neurologic worsening [
         <a href="#rid19">
          19
         </a>
         ], which may be overly inclusive because it captures small petechial hemorrhages associated with minimal neurologic deterioration that are unlikely to have altered long-term functional outcome [
         <a href="#rid27">
          27,28
         </a>
         ]. By contrast, the ECASS 2, ECASS-3 and SITS-MOST definitions of symptomatic intracerebral hemorrhage include only hemorrhage associated with substantial clinical worsening of ≥4 points on the National Institutes of Health Stroke Scale (NIHSS) stroke scale [
         <a href="#rid24">
          24,29,30
         </a>
         ], which may be more predictive of intracerebral hemorrhages that adversely affect long-term outcome. As an example, the SITS-MOST study enrolled over 30,000 patients, mainly from Europe, who were treated with intravenous
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         at 669 centers [
         <a href="#rid24">
          24
         </a>
         ]. Symptomatic intracerebral hemorrhage by the NINDS definition occurred in 7.4 percent, and by the SITS-MOST definition in 1.8 percent. Lower rates have also been reported in other trials using stricter definitions of symptomatic intracerebral hemorrhage, including ECASS 3 [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Several risk assessment methods, including the HAT score, DRAGON score, SEDAN score, Stroke-Thrombolytic Predictive Instrument, SPAN-100 index, and the SITS SICH risk score, have been devised to predict the risk of intracerebral hemorrhage and/or prognosis for patients with acute stroke who are treated with IVT [
         <a href="#rid24">
          24,31-39
         </a>
         ]. However, additional validation studies are needed to confirm the utility of these methods before they should be used in clinical practice.
        </p>
        <p class="headingAnchor" id="H94915205">
         <span class="h4">
          Recanalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Full or partial recanalization up to 24 hours after onset of acute stroke is associated with a more favorable outcome than persistent occlusion after thrombolysis [
         <a href="#rid40">
          40-44
         </a>
         ]. In a prospective, multicenter study of 575 patients with acute ischemic stroke and intracranial arterial occlusion on baseline CT angiography (CTA), the rate of successful recanalization detected on repeat CTA was greater for patients who received IVT compared with those who did not (30 versus 13 percent, absolute difference 17 percent, 95% CI 10-26 percent) [
         <a href="#rid45">
          45
         </a>
         ]. As observed in this and other studies, factors associated with the response to thrombolytic therapy include location of the symptomatic occlusive thrombus in the arterial tree, and clot-specific features such as size, composition, and source:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clot size and site
         </strong>
         – Larger clots and more proximal clots (versus more distal location) are more resistant to thrombolysis [
         <a href="#rid45">
          45-50
         </a>
         ]. As an example, internal carotid artery occlusions are more resistant than middle cerebral artery occlusions to IVT treatment. This may be due at least in part to the larger size of clots that lodge in larger vessels [
         <a href="#rid51">
          51
         </a>
         ]. Clot occluding the cervical internal carotid artery may promote adjacent thrombosis extending to the intracranial internal carotid artery, resulting in a very long thrombus that is unlikely to be lysed by IVT alone. In large vessels, in situ thromboses associated with atherosclerotic lesions may be more resistant to recanalization than fibrin rich embolic occlusions arising from the heart [
         <a href="#rid52">
          52
         </a>
         ]. In addition, higher residual flow (a measure of thrombus permeability) of intracranial arteries on baseline angiography is associated with successful recanalization [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clot age and composition
         </strong>
         – The age and composition of thromboembolic material likely affect its response to thrombolytic therapy [
         <a href="#rid53">
          53,54
         </a>
         ]. The ability to recanalize in experimental embolic stroke is related to the amount of red cells in the emboli and inversely related to the volume of emboli and to the fibrin content and density of the clots [
         <a href="#rid55">
          55
         </a>
         ]. Thrombolytic drugs are unlikely to disrupt other types of embolic material, such as calcific plaque and fat.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H72093666">
         <span class="h4">
          Other variables affecting outcome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early recanalization is probably the most important determinant of good outcome after thrombolysis, but a number of additional variables may impact neurologic outcome and the risk of intracerebral hemorrhage [
         <a href="#rid56">
          56,57
         </a>
         ]. These include age, sex, stroke severity, availability of collateral blood supply, and early ischemic change on CT or MRI. However, these factors do not necessarily predict which patients will or will not benefit from IVT. The only factor known to independently alter response to IVT is
         <strong>
          time to treatment
         </strong>
         . (See
         <a class="local">
          'Benefit by time to treatment'
         </a>
         above.)
        </p>
        <p>
         Whenever possible, the potential risks and benefits of thrombolysis should be discussed objectively with the patient and/or family or health care proxy prior to initiating treatment. (See
         <a class="local">
          'Issues regarding consent'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – Patients 80 years of age or older appear to benefit from IVT despite a higher mortality rate compared with younger patients. (See
         <a class="local">
          'Age 80 years and older'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stroke severity
         </strong>
         – The severity of neurologic deficit as measured on the NIHSS score  (
         <a class="graphic graphic_table graphicRef61698" href="/z/d/graphic/61698.html" rel="external">
          table 3
         </a>
         ) is associated with an increased risk of intracerebral hemorrhage [
         <a href="#rid6">
          6,58
         </a>
         ]. However, stroke severity alone cannot be used to select or exclude patients for IVT. A 2014 meta-analysis of individual patient data from 6756 subjects found that the benefit of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         was similar regardless of stroke severity [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early ischemic changes on CT
         </strong>
         – The presence of extensive regions of obvious hypodensity consistent with irreversible injury on initial head CT suggests a longer time since stroke onset and is an exclusion for use of IVT  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         ). This finding should be distinguished from milder early ischemic edema as discussed below. (See
         <a class="local">
          'Early ischemic changes on neuroimaging'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperglycemia
         </strong>
         – Hyperglycemia before reperfusion in patients with acute ischemic stroke has been associated with diminished neurologic improvement, greater infarct size, and worse clinical outcome at three months after treatment with IVT [
         <a href="#rid59">
          59-61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebral microbleeds
         </strong>
         – Cerebral microbleeds are small chronic hemorrhages that are best visualized on susceptibility-weighted MRI sequences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Meta-analyses published in 2015 [
         <a href="#rid62">
          62
         </a>
         ], 2016 [
         <a href="#rid63">
          63
         </a>
         ], and 2017 [
         <a href="#rid64">
          64
         </a>
         ] found that the presence of cerebral microbleeds on pretreatment brain MRI was associated with an increased risk of intracerebral hemorrhage (ICH) in patients treated with IVT for acute ischemic stroke. In one of these reports, the risk of symptomatic ICH was significantly greater for patients with a high burden of cerebral microbleeds (&gt;10) compared with patients who had a lower burden of microbleeds (1 to 10 or 0 to 10) [
         <a href="#rid63">
          63
         </a>
         ]. However, the small number of patients in the subgroup with &gt;10 microbleeds (n = 15) limits the strength of this conclusion. In another meta-analysis, the presence of cerebral microbleeds was not associated with symptomatic ICH but was associated with an increased risk of parenchymal hemorrhage, and the presence of &gt;5 cerebral microbleeds was associated with poor functional outcome at three to six months [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since decisions to proceed IVT treatment are usually made based upon CT imaging without MRI, these results should not affect patient selection or mandate additional imaging that will prolong the time to treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex
         </strong>
         – There are conflicting data regarding whether benefit from early IVT of acute ischemic stroke differs by sex [
         <a href="#rid65">
          65-67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H309224728">
         <span class="h3">
          Tenecteplase
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">
          Tenecteplase
         </a>
         , a type of recombinant tissue plasminogen activator (tPA), is a modified version of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         , the only approved tPA for treating acute ischemic stroke. Tenecteplase differs from human tPA by having three amino acid substitutions. Because of the modifications, tenecteplase is more fibrin-specific and has a longer duration of action compared with alteplase.
        </p>
        <p>
         The single bolus dosing of
         <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">
          tenecteplase
         </a>
         is far easier to give in an emergency department and translates into faster door-to-needle times compared with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Although not licensed in the US for IVT in acute ischemic stroke treatment, there is moderate- to high-quality evidence that intravenous
         <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">
          tenecteplase
         </a>
         , given in a single bolus at 0.25 mg/kg (maximum 25 mg), has similar efficacy and safety outcomes compared with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         , including rates of excellent functional outcome, symptomatic intracerebral hemorrhage, and mortality at 90 days [
         <a href="#rid68">
          68-83
         </a>
         ]. As an example, the EXTEND-IA TNK trial found that tenecteplase led to better functional outcomes compared with alteplase and higher rates of reperfusion of the involved ischemic territory [
         <a href="#rid70">
          70
         </a>
         ]. Furthermore, in an analysis of pooled individual patient data from several trials and a registry of patients with large vessel occlusion who were treated with intravenous thrombolysis, tenecteplase treatment (n = 492) compared with alteplase treatment (n = 401) was associated with higher rates of prethrombectomy reperfusion, which in turn was associated with improved outcomes [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         However, higher doses of
         <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">
          tenecteplase
         </a>
         (≥0.4 mg/kg) should not be used for IVT because such doses may be associated with harm, although the evidence is inconsistent. In the original NOR-TEST trial, most of the 1100 patients had minor strokes (the median NIHSS score was 4), and the tenecteplase group, treated with 0.4 mg/kg, had similar safety and efficacy outcomes compared with the
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         group [
         <a href="#rid69">
          69
         </a>
         ]. However, the NOR-TEST 2, part A trial was stopped early, after enrolling only 204 patients, due to higher numbers of symptomatic intracranial hemorrhage in the tenecteplase group [
         <a href="#rid85">
          85
         </a>
         ]. NOR-TEST 2 included patients with moderate to severe ischemic stroke (the median NIHSS was 11) who were within 4.5 hours of the time last known well; the patients were randomly assigned to tenecteplase 0.4 mg/kg or alteplase 0.9 mg/kg. At three months, compared with the alteplase group, the tenecteplase group showed a trend toward an increased rate of symptomatic intracranial hemorrhage (6 versus 1 percent, OR 6.57, 95% CI 0.78-55.62). Furthermore, the tenecteplase group had a lower rate of a favorable outcome, defined as an mRS score of 0 to 1 (32 versus 51 percent, OR 0.45, 95% CI 0.25-0.80), and a higher rate of mortality (16 versus 5 percent, OR 3.56, 95% CI 1.24-10.21).
        </p>
        <p class="headingAnchor" id="H2635432629">
         <span class="h2">
          Mechanical thrombectomy (MT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mechanical thrombectomy is indicated for patients with acute ischemic stroke due to a large artery occlusion in the anterior circulation who meet eligibility criteria and can be treated within 24 hours of the time last known to be well (ie, at neurologic baseline), regardless of whether they receive IVT for the same ischemic stroke event. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke"
         </a>
         .)
        </p>
        <p>
         Patient selection for MT  (
         <a class="graphic graphic_algorithm graphicRef141874" href="/z/d/graphic/141874.html" rel="external">
          algorithm 2
         </a>
         ) is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Patient selection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3233570024">
         <span class="h2">
          IVT followed by MT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with IVT prior to MT, known as bridging therapy, is recommended for most patients who are candidates for both reperfusion therapies. Patients with ischemic stroke from large vessel occlusion should receive IVT without delay, if eligible, even if MT is being considered [
         <a href="#rid86">
          86
         </a>
         ]. Mechanical thrombectomy treatment should then be started as quickly as possible [
         <a href="#rid87">
          87,88
         </a>
         ], and should not be delayed to assess the response to IVT.
        </p>
        <p>
         Potential advantages of IVT before MT include complete or partial lysis of the thrombus causing the large vessel occlusion (the target of MT), lysis of thrombotic emboli in distal vessels beyond the reach of MT, and faster resolution of brain ischemia [
         <a href="#rid89">
          89
         </a>
         ]. Potential disadvantages of giving IVT first include a delay in the time to the start of the MT procedure, an increased risk of symptomatic brain hemorrhage, and partial lysis of the large vessel thrombus that allows it to travel to more distal vessels beyond the reach of MT.
        </p>
        <p>
         MT alone (without preceding IVT) is an alternative strategy, but the available data, while inconsistent, have not proven the efficacy of this approach compared with the combination of IVT and MT for improved clinical outcomes or safety [
         <a href="#rid90">
          90-100
         </a>
         ]. The preponderance of the evidence is not definitive but favors bridging therapy over MT alone. A meta-analysis pooled patient-level data from six randomized controlled trials that included 1153 participants randomly assigned to receive MT alone and 1160 randomly assigned to receive IVT and MT [
         <a href="#rid101">
          101
         </a>
         ]. The ordinal logistic regression of a shift towards lower mRS scores favored IVT plus MT (adjusted common odds ratio [acOR] 0.89; 95% CI 0.76–1.04), but the difference was not statistically significant. There was no significant difference between the groups for rates of symptomatic intracranial hemorrhage or mortality.
        </p>
        <p class="headingAnchor" id="H3301330430">
         <span class="h1">
          RAPID EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         All adult patients with a clinical diagnosis of acute ischemic stroke should be rapidly screened for treatment with intravenous thrombolysis (IVT). Simultaneously, patients with suspected acute ischemic stroke involving the anterior circulation should be evaluated for mechanical thrombectomy (MT). (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2736038878">
         <span class="h2">
          Prehospital recognition and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Emergency medical responders should identify patients with a suspected stroke, preferably using a validated stroke screening tool (see
         <a class="medical medical_review" href="/z/d/html/14084.html" rel="external">
          "Use and utility of stroke scales and grading systems", section on 'Stroke diagnosis'
         </a>
         ), and transport them rapidly to the nearest medical facility that can provide urgent stroke care with the capability to treat with IVT, or IVT and MT.
        </p>
        <p>
         The use of mobile stroke units (MSUs) offers the potential for more rapid identification and treatment of acute ischemic stroke [
         <a href="#rid102">
          102,103
         </a>
         ]. MSUs are ambulances equipped with point-of-care laboratory testing and a CT scanner; they are staffed by medical personnel trained to diagnose and treat patients in the ambulance using thrombolytic therapy and to make triage decisions for mechanical thrombectomy, in conjunction with telemedicine communication to hospital stroke experts. However, MSUs are expensive, and availability is limited to only a few metropolitan areas throughout the world.
        </p>
        <p>
         The potential benefit of MSUs for improving outcome from acute ischemic stroke is illustrated by two prospective, nonrandomized controlled studies. One was a multicenter study from the United States of 1047 patients who were within 4.5 hours after stroke symptom onset; patients were assigned by week of enrollment to receive MSU or standard emergency medical services (EMS) care [
         <a href="#rid104">
          104
         </a>
         ]. Among patients eligible for intravenous thrombolysis, the rate of thrombolysis was higher in the MSU group compared with the EMS group (97.1 versus 79.5 percent), and the median time to thrombolysis was shorter (72 versus 108 minutes). At 90 days, the proportion of patients with no or minimal disability (ie, a score of 0 to 1 on the modified Rankin Scale [mRS]) was greater in the MSU group (53.5 versus 45.5 percent), while mortality was lower (8.9 versus 11.9 percent). The rate of symptomatic intracerebral hemorrhage in each group was 2 percent. In a similar prospective study of over 1500 patients from Berlin, Germany, dispatch of an MSU compared with EMS was associated with a shorter median time to treatment with thrombolysis (50 versus 70 minutes) and a lower level of global disability at 90 days [
         <a href="#rid105">
          105
         </a>
         ]. In a 2022 meta-analysis that included these two nonrandomized studies, MSU use was associated with higher rates of excellent outcome, defined by an mRS score of 0 to 1 at 90 days, compared with usual care (adjusted odds ratio [OR] 1.64, 95% CI 1.27-2.13) [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
         Further confirmation of clinical benefit along with evidence of cost-effectiveness will be needed before widespread use of MSUs can be considered. Other unproven strategies to reduce time to treatment with MT are being explored, including direct transport to a thrombectomy-capable center [
         <a href="#rid107">
          107
         </a>
         ], and even flying the thrombectomy intervention clinical team to the local stroke center [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1738200039">
         <span class="h2">
          In-hospital timeline
         </span>
         <span class="headingEndMark">
          —
         </span>
         A door-to-needle time of ≤60 minutes is the benchmark for achieving rapid treatment with IVT [
         <a href="#rid86">
          86
         </a>
         ]. The following in-hospital timeline is suggested as a goal for all patients with acute ischemic stroke who are eligible for treatment with IVT:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation by physician – 10 minutes elapsed from arrival
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stroke or neurologic expertise contacted (ie, stroke team) – ≤15 minutes elapsed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head CT or MRI scan – ≤25 minutes elapsed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interpretation of neuroimaging scan – ≤45 minutes elapsed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Start of IVT – ≤60 minutes elapsed
        </p>
        <p>
        </p>
        <p>
         Although IVT is the first priority, evaluation and preparation for possible MT should proceed during and after IVT. Patients with suspected infarction involving the anterior circulation should have cerebral angiography (eg, CT angiography [CTA] or magnetic resonance angiography [MRA]) as soon as possible to determine whether they have a proximal intracranial large artery occlusion that might also benefit from MT. However, IVT should not be delayed by angiography or MT.
        </p>
        <p>
         The administration of IVT for acute ischemic stroke, including dosing, monitoring, and complications, is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16134.html" rel="external">
          "Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3621933245">
         <span class="h2">
          Investigations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic neuroimaging is essential before considering reperfusion therapy for acute ischemic stroke. The only other test that is mandatory for all patients before initiation of IVT is blood glucose. In most cases, the results of routine laboratory tests including coagulation parameters and platelet count are not required to proceed with IVT. Thrombolytic therapy with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         (or
         <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">
          tenecteplase
         </a>
         ) should not be delayed while results are pending unless one of the following conditions is present [
         <a href="#rid86">
          86
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical suspicion of a bleeding abnormality or thrombocytopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current or recent use of anticoagulants (eg, heparin,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , direct oral anticoagulants [DOACs])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of anticoagulants is not known
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2871404843">
         <span class="h2">
          Potential exclusions to treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exclusion criteria for IVT are listed in the table  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         ); these criteria have evolved with time as experience with IVT has increased. Several clinical issues may complicate the decision to use reperfusion therapy for acute ischemic stroke. Among these are rapidly improving stroke symptoms and early ischemic changes on neuroimaging.
        </p>
        <p class="headingAnchor" id="H3569980306">
         <span class="h3">
          Patients on anticoagulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Current anticoagulant use with evidence of anticoagulant effect by laboratory tests is a contraindication to IVT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulation tests
         </strong>
         – For patients
         <strong>
          without
         </strong>
         recent use of oral anticoagulants or heparin, treatment with IVT can be started before availability of coagulation test results if there is no reason to suspect a coagulopathy (ie, patients not on anticoagulant therapy who have no known liver disease, hematologic disease, or advanced kidney disease). In such cases,
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         treatment should be discontinued if the international normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (aPTT) are excessively elevated  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         ). For patients with inadequate historical information, IVT should not be started until the aPTT and either the PT or the INR are available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Preliminary data suggest that normal coagulation parameters can be predicted on arrival to the emergency department by assessing three questions [
         <a href="#rid109">
          109
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Is the patient taking an oral anticoagulant?
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Is the patient taking heparin or low molecular weight heparin?
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Is the patient on hemodialysis?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a retrospective study from 2006 (prior to the advent of direct oral anticoagulants) that included 299 patients, "no" answers to all three questions predicted normal range PT and aPTT with a sensitivity of 100 percent, suggesting that this simple screen may permit earlier treatment with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         in selected patients with acute stroke [
         <a href="#rid109">
          109
         </a>
         ]. Other data suggest that unsuspected coagulopathy is rarely detected among patients evaluated for IVT [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients on DOACs
         </strong>
         – Accumulating evidence suggests that recent use of a DOAC is not associated with an increased risk of symptomatic intracerebral hemorrhage following IVT [
         <a href="#rid111">
          111,112
         </a>
         ]. Nevertheless, DOAC use remains a contraindication to IVT unless laboratory tests such as aPTT, INR, platelet count, ecarin clotting time, thrombin time, or appropriate direct factor Xa activity assays are normal
         <strong>
          or
         </strong>
         the patient has not received a DOAC dose for more than 48 hours, assuming normal renal function [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DOAC reversal
         </strong>
         – DOAC reversal may provide an option to safely treat with thrombolysis, although this approach is not yet established as safe [
         <a href="#rid113">
          113
         </a>
         ]. An observational cohort study identified 51 patients treated with
         <a class="drug drug_general" data-topicid="104819" href="/z/d/drug information/104819.html" rel="external">
          idarucizumab
         </a>
         for
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         reversal prior to thrombolysis and found that idarucizumab-treated patients had similar rates of symptomatic intracerebral hemorrhage, early neurologic improvement, and mortality compared with patients not treated with idarucizumab [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11734257">
         <span class="h3">
          Rapidly improving stroke symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapidly improving stroke symptoms (RISS) should be considered an exclusion for reperfusion therapy
         <strong>
          only
         </strong>
         for patients who improve to the degree that any remaining deficits are nondisabling [
         <a href="#rid115">
          115
         </a>
         ]. The decision regarding use of IVT or MT should be made based upon monitoring neurologic deficits for no longer than the time needed to prepare and begin treatment; treatment should not be delayed by continued monitoring for improvement.
        </p>
        <p class="headingAnchor" id="H1232731026">
         <span class="h3">
          Minor stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to treat minor stroke with IVT depends in part upon whether the deficits are potentially disabling, as described below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disabling
         </strong>
         – Qualifying patients who have an acute ischemic stroke causing a persistent neurologic deficit that is potentially disabling, despite improvement of any degree while being evaluated, should be treated urgently with IVT and/or MT as appropriate. Any of the following should be considered disabling deficits [
         <a href="#rid115">
          115
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete hemianopia: ≥2 on the National Institutes of Health Stroke Scale (NIHSS) question 3  (
         <a class="graphic graphic_table graphicRef61698" href="/z/d/graphic/61698.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe aphasia: ≥2 on NIHSS question 9  (
         <a class="graphic graphic_table graphicRef61698" href="/z/d/graphic/61698.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Visual extinction: ≥1 on NIHSS question 11  (
         <a class="graphic graphic_table graphicRef61698" href="/z/d/graphic/61698.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any weakness limiting sustained effort against gravity: ≥2 on NIHSS question 5 or 6  (
         <a class="graphic graphic_table graphicRef61698" href="/z/d/graphic/61698.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any deficits that lead to a total NIHSS &gt;5 (
         <a class="calc calc_professional" href="/z/d/html/91350.html" rel="external">
          calculator 1
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any remaining deficit considered potentially disabling by the patient, family, or the treating clinician
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with an NIHSS score of 0 to 5, a clearly disabling deficit has also been defined as one that would prevent the patient from performing basic activities of daily living (ie, bathing, walking, toileting, and eating) or returning to work [
         <a href="#rid116">
          116
         </a>
         ]. Examples include minor fine motor weakness and/or dysmetria in a concert pianist or mild dysarthria in a television or radio broadcaster. Other examples include clinically significant deficits not captured by the NIHSS, such as gait ataxia, dysphagia, or diplopia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nondisabling
         </strong>
         – Available evidence suggests that IVT is not beneficial for patients with mild, nondisabling ischemic stroke. The open-label ARAMIS trial enrolled patients in China with acute ischemic stroke within 4.5 hours of symptom onset who had an NIHSS score of ≤5 and nondisabling deficits, with ≤1 point for single-item NIHSS scores, including those for vision, language, neglect, and single limb weakness; and with a score of 0 (normal) for the consciousness item [
         <a href="#rid117">
          117
         </a>
         ]. Eligible patients (n = 760) were randomly assigned in a 1:1 ratio to treatment with dual antiplatelet therapy (DAPT) using
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         for approximately 12 days or to IVT with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         . After the initial randomized treatment, individuals in both groups received either single antiplatelet therapy or DAPT based upon guidelines for the duration of the trial. At 90 days, the rate of an excellent functional outcome (defined by an mRS score of 0 or 1) was similar for the DAPT and IVT groups (93.8 versus 91.4 percent, risk difference 2.3 percent, 95% CI -1.5 to 6.2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly, the PRISMS trial enrolled patients with acute ischemic stroke within 3 hours of symptom onset who had an NIHSS score ≤5 and deficits judged
         <strong>
          not
         </strong>
         clearly disabling; there was no difference at 90 days in the rate of a favorable functional outcome (defined as an mRS score of 0 or 1) for patients assigned to treatment with IVT or to
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (78.2 versus 81.5 percent) [
         <a href="#rid116">
          116
         </a>
         ]. However, the trial was stopped early solely because of slow recruitment, having enrolled only 313 of a planned 948 subjects, and therefore its findings are not definitive.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3544304113">
         <span class="h3">
          Early ischemic changes on neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Minor ischemic changes on CT are not a contraindication to treatment; these include subtle or small areas of hypodensity, loss of gray-white distinction, obscuration of the lentiform nucleus, or the presence of a hyperdense artery sign  (
         <a class="graphic graphic_diagnosticimage graphicRef121623" href="/z/d/graphic/121623.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
         We suggest withholding thrombolytic therapy with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         for patients with extensive regions of obvious hypodensity consistent with irreversible injury on initial head CT  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         ), although there are few data to determine a threshold of ischemic severity or extent that modifies treatment response to alteplase [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         Patient selection for MT is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Role of ASPECTS method'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3122554928">
         <span class="h2">
          Issues regarding consent
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          Alteplase
         </a>
         is an approved therapy for acute ischemic stroke because of substantial evidence of safety and efficacy. Consent is not required to administer alteplase as an emergent therapy for an otherwise eligible adult patient with a disabling acute ischemic stroke if patient or surrogate consent is not possible [
         <a href="#rid86">
          86
         </a>
         ]. In such cases, the need for informed consent is outweighed by the need for urgent intervention, and the patient can be treated under the principle of presumption of consent. Furthermore, given the lack of clinical equipoise (the benefit of alteplase clearly outweighs the harms), shared decision-making is not appropriate [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
         Whether to proceed to thrombolysis in an individual patient should be based upon a brief discussion of the risks and benefits with the patient and family or health care proxy, if possible. However, neurologic deficits caused by acute stroke often preclude the ability of the patient to participate in the decision.
        </p>
        <p class="headingAnchor" id="H4125246622">
         <span class="h3">
          Explaining benefits and risks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Procedures for informed decision-making and informed consent vary among different centers; we explain the risks and benefits of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         as follows [
         <a href="#rid119">
          119
         </a>
         ]:
        </p>
        <p>
         "There is a treatment for your stroke called
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         that must be given within 4.5 hours after the stroke started. It is a 'clot-buster' drug. Getting alteplase reduces your risk of being disabled. People who get alteplase for stroke have a better chance of recovering without disability and getting back to the activities they enjoy compared with people who do not receive the treatment. All medicines have some risk. With alteplase, there is a risk of serious bleeding. However, time is important as well. We know that the sooner we start treatment with alteplase, the greater the chance that patients will have a good outcome."
        </p>
        <p>
         Some patients will accept any risk, including an increased risk of intracranial bleeding, for an increased chance of avoiding severe permanent disability. Others are more risk averse and prefer to accept disability, especially if there is a chance of recovery over time.
        </p>
        <p class="headingAnchor" id="H1815300033">
         <span class="h2">
          Need for transfer to stroke center
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most hospitals in more economically developed countries are able to treat acute ischemic stroke with IVT. In situations where local stroke expertise is not routinely or immediately available, accumulating data suggest that the decision to administer IVT can be guided safely and effectively via telemedicine (telestroke) [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
         By contrast, MT is not as widely available. Transfer to an expert stroke center may be necessary for patients with acute ischemic stroke in the anterior circulation who present to medical facilities that lack resources and expertise to deliver MT. However, eligible patients can receive standard treatment with IVT if they present to hospitals where thrombectomy is not an option, and those with qualifying anterior circulation strokes can then be transferred to stroke centers where intra-arterial thrombectomy is available, a strategy called "drip and ship" [
         <a href="#rid121">
          121,122
         </a>
         ]. Screening of patients for transfer is aided by the ability of networked hospitals to share brain and neurovascular imaging studies via cloud computing, which allows the stroke center hub to read a CTA (or MRA) done locally and thereby determine whether the patient has a large vessel occlusion, a key requirement for MT.
        </p>
        <p class="headingAnchor" id="H3888816828">
         <span class="h2">
          Reducing delay
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inordinate treatment delay can occur during any of the steps involved in reperfusion therapy, including emergency department triaging, initial telephone triage by the stroke physician, physician evaluation, neuroimaging, obtaining and waiting for results of blood and laboratory tests, obtaining consent, treating hypertension that would otherwise exclude the use of IVT (ie, systolic blood pressure ≥185 mmHg or diastolic ≥110 mmHg), and delivery of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         from the pharmacy to the bedside. Expedited stroke protocols may reduce treatment delays and improving patient outcomes. Such protocols may include the following features [
         <a href="#rid123">
          123,124
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prehospital notification by emergency medical personnel/ambulance of a patient with a possible stroke
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blast paging of all relevant hospital stroke personnel, including CT technicians
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In-person triage of all code strokes without telephone triage; the stroke physician on-call proceeds immediately to the bedside
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct transfer of the patient, without fully undressing, from triage onto the CT scanner table via the ambulance stretcher
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No delays pending formal neuroimaging interpretation; the on-call stroke physician reads the brain CT or MRI scan
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unmixed
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         is available at the bedside during the evaluation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No delays pending electrocardiogram (ECG), coagulation tests, chest radiograph, or stool guaiac unless specifically indicated
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No delays pending written consent; verbal consent is obtained if the patient is able to consent or if family members or health care proxy are nearby
        </p>
        <p>
        </p>
        <p>
         While an expedited evaluation might increase the risk of giving IVT in cases of stroke mimics, data suggest that the intracranial hemorrhage rate in patients who later are diagnosed with a stroke mimic is approximately 1 percent [
         <a href="#rid125">
          125,126
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2387295613">
         <span class="h1">
          TREATMENT BY TIME FROM SYMPTOM ONSET
         </span>
         <span class="headingEndMark">
          —
         </span>
         "Time is brain." The sooner intravenous thrombolysis (IVT) treatment with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         is initiated after ischemic stroke, the more likely it is to be beneficial [
         <a href="#rid127">
          127-129
         </a>
         ]. Eligible patients should start treatment as quickly as possible within the appropriate 3- or 4.5-hour time window from stroke onset; treatment should not be delayed until the end of the time window.
        </p>
        <p>
         Mechanical thrombectomy (MT) is also time-dependent, with clear benefit for patients with acute ischemic stroke caused by an intracranial large artery occlusion in the proximal anterior circulation who are treated within 6 hours of symptom onset. Beyond 6 hours, MT may be an option at specialized stroke centers using imaging-based selection of patients with anterior circulation stroke who have symptom onset 6 to 24 hours before treatment. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3923506290">
         <span class="h2">
          Less than 3 hours
         </span>
         <span class="headingEndMark">
          —
         </span>
         For eligible patients with acute ischemic stroke causing a potentially disabling neurologic deficit, we recommend IVT with intravenous
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         (or intravenous
         <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">
          tenecteplase
         </a>
         ) when treatment is initiated within 3 hours of the time last known well. Patients in this time window should also be evaluated to determine if they are candidates for MT. (See
         <a class="local">
          'Benefit by time to treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3115618621">
         <span class="h2">
          3 to 4.5 hours
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefit of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         extends to 4.5 hours, as discussed above. For otherwise eligible patients who cannot be treated in less than 3 hours, we suggest (ie, a weak recommendation) IVT with alteplase provided that treatment is initiated within 3 to 4.5 hours of the time last known well. Patients in this time window should also be evaluated to determine if they are candidates for MT. (See
         <a class="local">
          'Benefit by time to treatment'
         </a>
         above.)
        </p>
        <p>
         There are additional exclusion criteria  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         ) for IVT in the 3- to 4.5-hour time window (age &gt;80 years old, an National Institutes of Health Stroke Scale (NIHSS) score &gt;25, a combination of previous stroke and diabetes, and oral anticoagulant use regardless of INR). However, we do not consider these as absolute contraindications to IVT in the 3- to 4.5-hour time window, given evidence that
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         is still beneficial in patients who would otherwise be excluded by these criteria [
         <a href="#rid4">
          4,118,130,131
         </a>
         ]. The additional exclusions from 3 to 4.5 hours were made to satisfy safety concerns from the European regulatory agency and were employed to select patients for treatment in the ECASS 3 trial [
         <a href="#rid29">
          29
         </a>
         ], which established the benefit of IVT in the 3- to 4.5-hour time window.
        </p>
        <p class="headingAnchor" id="H1005401563">
         <span class="h2">
          4.5 to 6 hours
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients within 4.5 to 6 hours from stroke symptom onset should
         <strong>
          not
         </strong>
         routinely receive IVT because harm may exceed benefit, but they should be evaluated to determine if they are candidates for MT. (See
         <a class="local">
          'Benefit by time to treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1549792853">
         <span class="h2">
          6 to 24 hours
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients beyond 6 hours from ischemic stroke symptom onset are not eligible for treatment with IVT. However, MT is an option at specialized stroke centers using imaging-based selection of patients with anterior circulation stroke who have were last known to be well at 6 to 24 hours before treatment. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Benefit of later (6 to 24 hours) treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1464548903">
         <span class="h2">
          Beyond 24 hours
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients beyond 24 hours from ischemic stroke symptom onset generally are not eligible for treatment with IVT or MT. Limited retrospective data suggest possible benefit for selected patients treated with MT beyond 24 hours of last known well, but confirmation from prospective trials is needed [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1983884854">
         <span class="h2">
          Unwitnessed stroke onset and "wake-up" stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the exact time of stroke onset is not known, it is defined as the last time the patient was known to be normal. For patients whose stroke symptoms are first noted upon awakening from sleep, the last time known to be normal may be the time they went to bed (if the patient can report this reliably) or the last time seen normal by a friend or family member. Such patients are not ordinarily eligible for IVT unless the time last known to be normal is less than 4.5 hours. However, imaging-based criteria (ie, MRI showing an acute ischemic lesion that is diffusion positive and fluid-attenuated inversion recovery [FLAIR] negative) is an option at expert stroke centers to select patients with wake-up stroke or unknown stroke onset time for IVT. (See
         <a class="local">
          'Benefit with imaging selection of patients'
         </a>
         above.)
        </p>
        <p>
         Imaging-based selection of patients for treatment with MT who were last known to be normal 6 to 24 hours before treatment is an option at specialized stroke centers. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Benefit of later (6 to 24 hours) treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4049847452">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Different clinical presentations and patient populations may affect the decision to use intravenous thrombolysis (IVT) or mechanical thrombectomy (MT) for acute ischemic stroke, as discussed below.
        </p>
        <p class="headingAnchor" id="H4073362228">
         <span class="h2">
          Posterior circulation stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         All eligible patients with acute ischemic stroke should be treated with IVT, including those with stroke in the posterior circulation. Mechanical thrombectomy is beneficial for select patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion in the anterior circulation, but trials that established the benefit of MT largely excluded patients with posterior circulation infarcts. However, endovascular interventions for vertebrobasilar occlusions, including MT, may be treatment options stroke centers with appropriate expertise. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Posterior circulation stroke'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1712380566">
         <span class="h2">
          Age 80 years and older
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients 80 years of age or older appear to benefit from IVT despite a higher mortality rate compared with younger patients. Therefore, we do
         <strong>
          not
         </strong>
         consider age to be a contraindication to IVT treatment for otherwise eligible patients. However, age &gt;80 years is a relative contraindication in the 3- to 4.5-hour time window. (See
         <a class="local">
          '3 to 4.5 hours'
         </a>
         above.)
        </p>
        <p>
         A 2014 meta-analysis of individual patient data from 6756 subjects (including more than 1700 subjects older than age 80 years) found that benefit of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         was similar regardless of patient age [
         <a href="#rid4">
          4
         </a>
         ]. In a prespecified secondary analysis of individual participant data (n = 6756) from a 2016 meta-analysis of nine trials of alteplase versus control for acute ischemic stroke, the increased risk of intracerebral hemorrhage with alteplase in the first seven days after treatment did not differ by age [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Older age is not an exclusion for MT [
         <a href="#rid133">
          133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Patient selection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3607904994">
         <span class="h2">
          Prestroke disability or dementia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment decisions regarding IVT or MT for patients with significant prestroke disability or dementia should be individualized using shared decision-making that incorporates patient values and preferences [
         <a href="#rid134">
          134
         </a>
         ]. Such patients were largely excluded from randomized trials of reperfusion therapies for acute ischemic stroke. However, observational data suggest that patients with disability or dementia at baseline may still benefit from reperfusion for acute stroke, despite an overall worse prognosis and possibly higher mortality [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3232092298">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although pregnancy has been considered a relative contraindication to the use of thrombolysis for acute stroke, IVT can be given in pregnancy after careful discussion of the potential risks and benefits. The use of thrombolytic therapy in pregnancy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1108.html" rel="external">
          "Cerebrovascular disorders complicating pregnancy", section on 'Acute ischemic stroke'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2910250545">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Safety and efficacy data for reperfusion therapy of acute ischemic stroke are lacking in patients younger than 18 years of age. However, IVT and MT may be options for some children, particularly adolescents (age ≥13 years), with acute ischemic stroke on neuroimaging who are evaluated and treated at pediatric stroke centers. (See
         <a class="medical medical_review" href="/z/d/html/6215.html" rel="external">
          "Ischemic stroke in children: Management and prognosis", section on 'Reperfusion with thrombolysis and thrombectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1472337320">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">
          "Society guideline links: Stroke in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2219707362">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals and options for reperfusion
         </strong>
         – The immediate goal of reperfusion therapy for acute ischemic stroke is to restore blood flow to the regions of brain that are ischemic but not yet infarcted. Intravenous thrombolysis (IVT) is the mainstay of reperfusion therapy for acute ischemic stroke. Mechanical thrombectomy (MT) is indicated for patients with acute ischemic stroke caused by an intracranial large artery occlusion in the proximal anterior circulation. (See
         <a class="local">
          'Reperfusion therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit of reperfusion therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IVT improves functional outcome at three to six months for appropriately selected patients  (
         <a class="graphic graphic_algorithm graphicRef141876" href="/z/d/graphic/141876.html" rel="external">
          algorithm 1
         </a>
         ) when given within 4.5 hours of ischemic stroke onset. (See
         <a class="local">
          'Alteplase'
         </a>
         above and
         <a class="local">
          'Tenecteplase'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MT improves functional outcome at three months for appropriately selected patients  (
         <a class="graphic graphic_algorithm graphicRef141874" href="/z/d/graphic/141874.html" rel="external">
          algorithm 2
         </a>
         ) if treatment is started within 24 hours from the time the patient was last known well. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Efficacy of mechanical thrombectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – All adult patients with a clinical diagnosis of acute ischemic stroke should be rapidly evaluated for treatment with IVT. Simultaneously, patients with suspected acute ischemic stroke involving the anterior circulation should be evaluated for MT. (See
         <a class="local">
          'Rapid evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          For IVT
         </strong>
         – Eligibility criteria for treatment with IVT are outlined in the table  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef141876" href="/z/d/graphic/141876.html" rel="external">
          algorithm 1
         </a>
         ). For eligible patients with acute ischemic stroke causing a potentially disabling neurologic deficit, we recommend IVT with
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         , provided that treatment is initiated within 3 hours of the time last known well (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). For otherwise eligible patients who cannot be treated in less than 3 hours, we suggest IVT, provided that treatment is initiated within 3 to 4.5 hours of the time last known well (
         <a class="grade" href="https:///uptodate/show/grade_4" rel="external">
          Grade 2A
         </a>
         ). For patients with wake-up stroke or unknown stroke onset time, imaging-based criteria (ie, MRI showing an acute ischemic lesion that is diffusion positive and fluid-attenuated inversion recovery [FLAIR] negative) is an option at expert stroke centers to determine eligibility for IVT. (See
         <a class="local">
          'Less than 3 hours'
         </a>
         above and
         <a class="local">
          '3 to 4.5 hours'
         </a>
         above and
         <a class="local">
          'Unwitnessed stroke onset and "wake-up" stroke'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          For MT
         </strong>
         – Intra-arterial mechanical thrombectomy is recommended for patients with ischemic stroke caused by a large artery occlusion in the proximal anterior circulation who can start treatment within 24 hours of the time last known well  (
         <a class="graphic graphic_algorithm graphicRef141874" href="/z/d/graphic/141874.html" rel="external">
          algorithm 2
         </a>
         ). Indications and eligibility criteria for MT are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Patient selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          IVT administration
         </strong>
         – The administration of IVT for acute ischemic stroke, including dosing, monitoring, and complications, is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16134.html" rel="external">
          "Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MT procedure
         </strong>
         – Procedural details for MT are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke", section on 'Procedure'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013; 309:2480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:2364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA 2015; 313:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol 2016; 15:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees KR, Emberson J, Blackwell L, et al. Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials. Stroke 2016; 47:2373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mun KT, Bonomo JB, Liebeskind DS, Saver JL. Fragility Index Meta-Analysis of Randomized Controlled Trials Shows Highly Robust Evidential Strength for Benefit of &lt;3 Hour Intravenous Alteplase. Stroke 2022; 53:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goyal M, Almekhlafi M, Dippel DW, et al. Rapid Alteplase Administration Improves Functional Outcomes in Patients With Stroke due to Large Vessel Occlusions. Stroke 2019; 50:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Man S, Xian Y, Holmes DN, et al. Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. JAMA 2020; 323:2170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med 2018; 379:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomalla G, Cheng B, Ebinger M, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 2011; 10:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med 2019; 380:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringleb P, Bendszus M, Bluhmki E, et al. Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. Int J Stroke 2019; 14:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet 2019; 394:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomalla G, Boutitie F, Ma H, et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet 2020; 396:1574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall RS. Image-Guided Intravenous Alteplase for Stroke - Shattering a Time Window. N Engl J Med 2019; 380:1865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roaldsen MB, Eltoft A, Wilsgaard T, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol 2023; 22:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaMonte MP, Bahouth MN, Magder LS, et al. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial. Ann Emerg Med 2009; 54:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012; 43:1524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 2007; 38:2279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seet RC, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis 2012; 34:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao NM, Levine SR, Gornbein JA, Saver JL. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke 2014; 45:2728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gumbinger C, Gruschka P, Böttinger M, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke 2012; 43:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lou M, Safdar A, Mehdiratta M, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology 2008; 71:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology 2012; 78:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent DM, Selker HP, Ruthazer R, et al. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006; 37:2957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMeekin P, Flynn D, Ford GA, et al. Validating the stroke-thrombolytic predictive instrument in a population in the United kingdom. Stroke 2012; 43:3378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saposnik G, Guzik AK, Reeves M, et al. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology 2013; 80:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cucchiara B, Tanne D, Levine SR, et al. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis 2008; 17:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung SF, Chen SC, Lin HJ, et al. Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2013; 44:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol 2012; 71:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent DM, Ruthazer R, Decker C, et al. Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument. Neurology 2015; 85:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann-Haefelin T, du Mesnil de Rochemont R, Fiebach JB, et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke 2004; 35:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wunderlich MT, Goertler M, Postert T, et al. Recanalization after intravenous thrombolysis: does a recanalization time window exist? Neurology 2007; 68:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010; 41:2254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kharitonova TV, Melo TP, Andersen G, et al. Importance of cerebral artery recanalization in patients with stroke with and without neurological improvement after intravenous thrombolysis. Stroke 2013; 44:2513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Kummer R, Holle R, Rosin L, et al. Does arterial recanalization improve outcome in carotid territory stroke? Stroke 1995; 26:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon BK, Al-Ajlan FS, Najm M, et al. Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke. JAMA 2018; 320:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolpert SM, Bruckmann H, Greenlee R, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993; 14:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez JI, Sunshine JL, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke 1999; 30:2094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linfante I, Llinas RH, Selim M, et al. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke 2002; 33:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007; 38:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo J, Baek JH, Park H, et al. Thrombus Volume as a Predictor of Nonrecanalization After Intravenous Thrombolysis in Acute Stroke. Stroke 2018; 49:2108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seners P, Turc G, Maïer B, et al. Incidence and Predictors of Early Recanalization After Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Stroke 2016; 47:2409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina CA, Montaner J, Arenillas JF, et al. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004; 35:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulgham JR, Ingall TJ, Stead LG, et al. Management of acute ischemic stroke. Mayo Clin Proc 2004; 79:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EY, Heo JH, Lee SK, et al. Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT. Neurology 2006; 67:1846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard K. Thrombolytic therapy in experimental embolic stroke. Cerebrovasc Brain Metab Rev 1994; 6:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karaszewski B, Houlden H, Smith EE, et al. What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers. J Neurol Neurosurg Psychiatry 2015; 86:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leng X, Lan L, Liu L, et al. Good collateral circulation predicts favorable outcomes in intravenous thrombolysis: a systematic review and meta-analysis. Eur J Neurol 2016; 23:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whiteley WN, Slot KB, Fernandes P, et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012; 43:2904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez-Sabín J, Molina CA, Montaner J, et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients. Stroke 2003; 34:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed N, Dávalos A, Eriksson N, et al. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 2010; 67:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masrur S, Cox M, Bhatt DL, et al. Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post-Thrombolysis: Findings From Get With The Guidelines-Stroke. J Am Heart Assoc 2015; 4:e002193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Shoamanesh A, Wilson D, et al. Cerebral microbleeds and postthrombolysis intracerebral hemorrhage risk Updated meta-analysis. Neurology 2015; 85:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke and High Cerebral Microbleed Burden: A Meta-analysis. JAMA Neurol 2016; 73:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Turc G, Oppenheim C, et al. Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis. Stroke 2017; 48:2084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent DM, Price LL, Ringleb P, et al. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 2005; 36:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meseguer E, Mazighi M, Labreuche J, et al. Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: a clinical registry study and systematic review. Stroke 2009; 40:2104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hametner C, MacIsaac RL, Kellert L, et al. Sex and Stroke in Thrombolyzed Patients and Controls. Stroke 2017; 48:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warach SJ, Dula AN, Milling TJ, et al. Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice. Stroke 2022; 53:3583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 2017; 16:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med 2018; 378:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thelengana A, Radhakrishnan DM, Prasad M, et al. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. Acta Neurol Belg 2019; 119:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kvistad CE, Novotny V, Kurz MW, et al. Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. Stroke 2019; 50:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgos AM, Saver JL. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials. Stroke 2019; 50:2156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA 2020; 323:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsanos AH, Safouris A, Sarraj A, et al. Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis. Stroke 2021; 52:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022; 400:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahawish K, Gommans J, Kleinig T, et al. Switching to Tenecteplase for Stroke Thrombolysis: Real-World Experience and Outcomes in a Regional Stroke Network. Stroke 2021; 52:e590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potla N, Ganti L. Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review. Int J Emerg Med 2022; 15:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsivgoulis G, Katsanos AH, Christogiannis C, et al. Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke. Ann Neurol 2022; 92:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 2023; 401:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose D, Cavalier A, Kam W, et al. Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke 2023; 54:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bala F, Singh N, Buck B, et al. Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke: A Prespecified Secondary Analysis of the ACT Randomized Clinical Trial. JAMA Neurol 2023; 80:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warach SJ, Ranta A, Kim J, et al. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. JAMA Neurol 2023; 80:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yogendrakumar V, Beharry J, Churilov L, et al. Tenecteplase Improves Reperfusion across Time in Large Vessel Stroke. Ann Neurol 2023; 93:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol 2022; 21:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019; 50:e344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jahan R, Saver JL, Schwamm LH, et al. Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice. JAMA 2019; 322:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunz WG, Hunink MG, Almekhlafi MA, et al. Public health and cost consequences of time delays to thrombectomy for acute ischemic stroke. Neurology 2020; 95:e2465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saver JL, Adeoye O. Intravenous Thrombolysis Before Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA 2021; 325:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang P, Zhang Y, Zhang L, et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. N Engl J Med 2020; 382:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Wu X, Zhu C, et al. Bridging Thrombolysis Achieved Better Outcomes Than Direct Thrombectomy After Large Vessel Occlusion: An Updated Meta-Analysis. Stroke 2021; 52:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zi W, Qiu Z, Li F, et al. Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. JAMA 2021; 325:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki K, Matsumaru Y, Takeuchi M, et al. Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial. JAMA 2021; 325:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeCouffe NE, Kappelhof M, Treurniet KM, et al. A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. N Engl J Med 2021; 385:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douarinou M, Gory B, Consoli A, et al. Impact of Strategy on Clinical Outcome in Large Vessel Occlusion Stroke Successfully Reperfused: ETIS Registry Results. Stroke 2022; 53:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet 2022; 400:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell PJ, Yan B, Churilov L, et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet 2022; 400:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trifan G, Biller J, Testai FD. Mechanical Thrombectomy vs Bridging Therapy for Anterior Circulation Large Vessel Occlusion Stroke: Systematic Review and Meta-analysis. Neurology 2022; 98:e1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith EE, Zerna C, Solomon N, et al. Outcomes After Endovascular Thrombectomy With or Without Alteplase in Routine Clinical Practice. JAMA Neurol 2022; 79:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsanos AH, Sarraj A, Froehler M, et al. IV Thrombolysis Initiated Before Transfer for Endovascular Stroke Thrombectomy: A Systematic Review and Meta-analysis. Neurology 2023; 100:e1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majoie CB, Cavalcante F, Gralla J, et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials. Lancet 2023; 402:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris J. A review of mobile stroke units. J Neurol 2021; 268:3180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fassbender K, Merzou F, Lesmeister M, et al. Impact of mobile stroke units. J Neurol Neurosurg Psychiatry 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grotta JC, Yamal JM, Parker SA, et al. Prospective, Multicenter, Controlled Trial of Mobile Stroke Units. N Engl J Med 2021; 385:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebinger M, Siegerink B, Kunz A, et al. Association Between Dispatch of Mobile Stroke Units and Functional Outcomes Among Patients With Acute Ischemic Stroke in Berlin. JAMA 2021; 325:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turc G, Hadziahmetovic M, Walter S, et al. Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management: A Systematic Review and Meta-analysis. JAMA Neurol 2022; 79:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez de la Ossa N, Abilleira S, Jovin TG, et al. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial. JAMA 2022; 327:1782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubert GJ, Hubert ND, Maegerlein C, et al. Association Between Use of a Flying Intervention Team vs Patient Interhospital Transfer and Time to Endovascular Thrombectomy Among Patients With Acute Ischemic Stroke in Nonurban Germany. JAMA 2022; 327:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottesman RF, Alt J, Wityk RJ, Llinas RH. Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use. Neurology 2006; 67:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rost NS, Masrur S, Pervez MA, et al. Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology 2009; 73:1957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahjouei S, Tsivgoulis G, Goyal N, et al. Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. Stroke 2020; 51:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kam W, Holmes DN, Hernandez AF, et al. Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA 2022; 327:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seiffge DJ, Meinel T, Purrucker JC, et al. Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. J Neurol Neurosurg Psychiatry 2021; 92:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber PA, Wu TY, Ranta A. Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort. Neurology 2020; 94:e1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force:, Levine SR, Khatri P, et al. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms. Stroke 2013; 44:2500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatri P, Kleindorfer DO, Devlin T, et al. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA 2018; 320:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen HS, Cui Y, Zhou ZH, et al. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA 2023; 329:2135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016; 47:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skolarus LE, O'Brien A, Meurer WJ, Zikmund Fisher BJ. Getting the Gist Across Is Enough for Informed Consent for Acute Stroke Thrombolytics. Stroke 2019; 50:1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kepplinger J, Barlinn K, Deckert S, et al. Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis. Neurology 2016; 87:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheth KN, Smith EE, Grau-Sepulveda MV, et al. Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes. Stroke 2015; 46:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deguchi I, Mizuno S, Kohyama S, et al. Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke. J Stroke Cerebrovasc Dis 2018; 27:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattin JA, Olson SE, Liu L, et al. An expedited code stroke protocol is feasible and safe. Stroke 2006; 37:2935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology 2013; 81:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keselman B, Cooray C, Vanhooren G, et al. Intravenous thrombolysis in stroke mimics: results from the SITS International Stroke Thrombolysis Register. Eur J Neurol 2019; 26:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsivgoulis G, Zand R, Katsanos AH, et al. Safety of intravenous thrombolysis in stroke mimics: prospective 5-year study and comprehensive meta-analysis. Stroke 2015; 46:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strbian D, Soinne L, Sairanen T, et al. Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality. Stroke 2010; 41:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebinger M, Winter B, Wendt M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA 2014; 311:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014; 311:1632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin CA, Shah N, Morovati T, et al. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria. Stroke 2012; 43:1684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill MD, Coutts SB. Alteplase in acute ischaemic stroke: the need for speed. Lancet 2014; 384:1904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarraj A, Kleinig TJ, Hassan AE, et al. Association of Endovascular Thrombectomy vs Medical Management With Functional and Safety Outcomes in Patients Treated Beyond 24 Hours of Last Known Well: The SELECT Late Study. JAMA Neurol 2023; 80:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonough RV, Ospel JM, Campbell BCV, et al. Functional Outcomes of Patients ≥85 Years With Acute Ischemic Stroke Following EVT: A HERMES Substudy. Stroke 2022; 53:2220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganesh A, Fraser JF, Gordon Perue GL, et al. Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability or Dementia: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke 2022; 53:e204.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 115775 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20472172" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23780461" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22632907" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25106063" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25871671" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acute stroke intervention: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27289487" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27507856" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35543129" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Fragility Index Meta-Analysis of Randomized Controlled Trials Shows Highly Robust Evidential Strength for Benefit of&lt;3 Hour Intravenous Alteplase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30760169" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Rapid Alteplase Administration Improves Functional Outcomes in Patients With Stroke due to Large Vessel Occlusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32484532" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29766770" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21978972" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31067369" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30947642" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31128925" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33176180" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31067378" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Image-Guided Intravenous Alteplase for Stroke - Shattering a Time Window.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36549308" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7477192" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tissue plasminogen activator for acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10703776" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19101059" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15883405" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17258667" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22442178" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17641238" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22868870" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25096731" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21998049" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18815396" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9788453" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955684" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22311929" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17068305" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23010676" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Validating the stroke-thrombolytic predictive instrument in a population in the United kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23175723" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18984422" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23632979" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22522478" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26291280" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671246" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452580" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Recanalization after intravenous thrombolysis: does a recanalization time window exist?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20829513" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23881960" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Importance of cerebral artery recanalization in patients with stroke with and without neurological improvement after intravenous thrombolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7709401" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Does arterial recanalization improve outcome in carotid territory stroke?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30208455" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8427107" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10512912" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12154264" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17290031" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30354986" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Thrombus Volume as a Predictor of Nonrecanalization After Intravenous Thrombolysis in Acute Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27462117" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Incidence and Predictors of Early Recanalization After Intravenous Thrombolysis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14707233" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15544028" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Management of acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17130421" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7811566" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Thrombolytic therapy in experimental embolic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25814492" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27478977" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Good collateral circulation predicts favorable outcomes in intravenous thrombolysis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22996959" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12677014" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20837858" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26408015" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post-Thrombolysis: Findings From Get With The Guidelines-Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26296519" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cerebral microbleeds and postthrombolysis intracerebral hemorrhage risk Updated meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27088650" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Risk of Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke and High Cerebral Microbleed Burden: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28720659" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15569865" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19372440" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: a clinical registry study and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28028149" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Sex and Stroke in Thrombolyzed Patients and Controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36148657" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28780236" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29694815" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29728903" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31009339" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31318627" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32078683" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33272127" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35779553" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34465202" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Switching to Tenecteplase for Stroke Thrombolysis: Real-World Experience and Outcomes in a Regional Stroke Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34983359" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35713213" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36774935" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36951049" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37428494" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke: A Prespecified Secondary Analysis of the ACT Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37252708" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36394101" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Tenecteplase Improves Reperfusion across Time in Large Vessel Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35525250" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31662037" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31310296" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32943483" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Public health and cost consequences of time delays to thrombectomy for acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33464293" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Intravenous Thrombolysis Before Endovascular Thrombectomy for Acute Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32374959" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33302795" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Bridging Thrombolysis Achieved Better Outcomes Than Direct Thrombectomy After Large Vessel Occlusion: An Updated Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33464335" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33464334" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34758251" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34727741" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Impact of Strategy on Clinical Outcome in Large Vessel Occlusion Stroke Successfully Reperfused: ETIS Registry Results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35810756" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35810757" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35173017" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Mechanical Thrombectomy vs Bridging Therapy for Anterior Circulation Large Vessel Occlusion Stroke: Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35696198" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Outcomes After Endovascular Thrombectomy With or Without Alteplase in Routine Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36581469" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : IV Thrombolysis Initiated Before Transfer for Endovascular Stroke Thrombectomy: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37640037" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32424611" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A review of mobile stroke units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34035130" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Impact of mobile stroke units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34496173" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Prospective, Multicenter, Controlled Trial of Mobile Stroke Units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33528537" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Association Between Dispatch of Mobile Stroke Units and Functional Outcomes Among Patients With Acute Ischemic Stroke in Berlin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35129584" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35510397" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35510389" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Association Between Use of a Flying Intervention Team vs Patient Interhospital Transfer and Time to Endovascular Thrombectomy Among Patients With Acute Ischemic Stroke in Nonurban Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17101901" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19940272" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31884908" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35143601" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33542084" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32079737" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23847249" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29998337" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37367978" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26696642" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31084320" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Getting the Gist Across Is Enough for Informed Consent for Acute Stroke Thrombolytics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27566746" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25672784" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28867523" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17095736" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : An expedited code stroke protocol is feasible and safe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23946303" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30793434" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Intravenous thrombolysis in stroke mimics: results from the SITS International Stroke Thrombolysis Register.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25791717" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Safety of intravenous thrombolysis in stroke mimics: prospective 5-year study and comprehensive meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20167917" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24756512" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24756513" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22535272" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25106064" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Alteplase in acute ischaemic stroke: the need for speed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36574257" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Association of Endovascular Thrombectomy vs Medical Management With Functional and Safety Outcomes in Patients Treated Beyond 24 Hours of Last Known Well: The SELECT Late Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35703094" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Functional Outcomes of Patients≥85 Years With Acute Ischemic Stroke Following EVT: A HERMES Substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35343235" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability or Dementia: A Scientific Statement From the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
